CA3012199C - Neurodevelopmental disorder therapy - Google Patents

Neurodevelopmental disorder therapy Download PDF

Info

Publication number
CA3012199C
CA3012199C CA3012199A CA3012199A CA3012199C CA 3012199 C CA3012199 C CA 3012199C CA 3012199 A CA3012199 A CA 3012199A CA 3012199 A CA3012199 A CA 3012199A CA 3012199 C CA3012199 C CA 3012199C
Authority
CA
Canada
Prior art keywords
day
syndrome
mice
dosage form
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3012199A
Other languages
English (en)
French (fr)
Other versions
CA3012199A1 (en
Inventor
Christopher U. Missling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anavex Life Sciences Corp
Original Assignee
Anavex Life Sciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57966177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3012199(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anavex Life Sciences Corp filed Critical Anavex Life Sciences Corp
Publication of CA3012199A1 publication Critical patent/CA3012199A1/en
Application granted granted Critical
Publication of CA3012199C publication Critical patent/CA3012199C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3012199A 2016-01-26 2017-01-24 Neurodevelopmental disorder therapy Active CA3012199C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662287062P 2016-01-26 2016-01-26
US62/287,062 2016-01-26
PCT/US2017/014702 WO2017132127A1 (en) 2016-01-26 2017-01-24 Neurodevelopmental disorder therapy

Publications (2)

Publication Number Publication Date
CA3012199A1 CA3012199A1 (en) 2017-08-03
CA3012199C true CA3012199C (en) 2024-05-07

Family

ID=57966177

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3012199A Active CA3012199C (en) 2016-01-26 2017-01-24 Neurodevelopmental disorder therapy

Country Status (5)

Country Link
US (5) US10507196B2 (https=)
EP (2) EP3407880B1 (https=)
JP (3) JP6866379B2 (https=)
CA (1) CA3012199C (https=)
WO (1) WO2017132127A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132127A1 (en) * 2016-01-26 2017-08-03 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy
US11337953B2 (en) 2016-07-27 2022-05-24 Anavex Life Sciences Corp. A2-73 as a therapeutic for insomnia, anxiety, and agitation
JP7532718B2 (ja) * 2018-04-12 2024-08-14 アナベックス ライフ サイエンス コーポレイション 物質のａ２－７３結晶多形組成物およびそれらの使用方法
AU2019269739B2 (en) 2018-05-18 2025-12-18 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
EP3990114A4 (en) * 2019-06-26 2023-08-02 The Regents of the University of California Methods and compositions for treating smith-magenis syndrome
US20220249427A1 (en) * 2019-07-22 2022-08-11 Anavex Life Sciences Corp. Anavex2-73 for the treatment of genetic neurodevelopmental disorders
US12397197B2 (en) 2023-11-08 2025-08-26 CaddyHack, Inc. Dynamic data collection and systematic processing system
WO2025231180A1 (en) * 2024-05-01 2025-11-06 Anavex Life Sciences Corp. Blarcamesine correction of eeg biomarkers in fragile x syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002616B (el) 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
GR1004208B (en) 2001-10-15 2003-04-04 Αλεξανδρος Βαμβακιδης Aminotetrahydrofuran derivatives, muscarinic/sigma/sodium channel ligands, with synergic sigma/muscarinic (neuroactivating) and sigma/sodium channel (neuroprotective) components, as prototypical activating - neuroprotectors and neuroregenerative drugs
FR2897535B1 (fr) 2006-02-21 2012-07-20 Alexandre Vamvakides Les sigma ligands : (mono- ou di-alkylaminoalkyl)-y- butyrolactones, leurs analogues aminotetrodrafuranes et les (1-adamantyl) benzene(s) alkylamines en tant que modulateurs prototypiques des recepteurs cellulaires
FR2908995B1 (fr) * 2006-11-24 2009-02-06 Servier Lab Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement du syndrome de smith magenis
GR1005865B (el) * 2007-01-17 2008-04-07 Anavex Life Sciences Corp. Νεοι συνδετες των σιγμα υποδοχεων με αντι-αποπτωτικες και/η προ-αποπτωτικες ιδιοτητες επι των κυτταρικων βιοχημικων μηχανισμων, με νευρο-προστατευτικη, αντικαρκινικη, αντι-μεταστατικη και αντι- αντι-(χρονιο)φλεγμονικη δραση.
CA2689549A1 (en) 2007-06-08 2008-12-18 Massachusetts Institute Of Technology Igf for the treatment of rett syndrome and synaptic disorders
GR1006794B (el) 2009-02-26 2010-06-04 Αλεξανδρος Βαμβακιδης Προσδετες των σιγμα υποδοχεων, αντι-αποπτωτικες και προ-αποπτωτικες ιδιοτητες επι των κυτταρικων μηχανισμων, και με πρωτοτυπη κυτταρο-προστατευτικη αλλα και αντικαρκινικη δραση
WO2011109398A2 (en) * 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2012055826A1 (en) 2010-10-25 2012-05-03 Universite De La Mediterranee (Aix-Marseille Ii) TREATMENT OF MeCP2-ASSOCIATED DISORDERS
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
US10555916B2 (en) * 2013-01-25 2020-02-11 Case Western Reserve University NMDAR antagonist for the treatment of pervasive development disorders
WO2017132127A1 (en) * 2016-01-26 2017-08-03 Anavex Life Sciences Corp. Neurodevelopmental disorder therapy
AU2019269739B2 (en) * 2018-05-18 2025-12-18 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment

Also Published As

Publication number Publication date
US20200246303A1 (en) 2020-08-06
EP3407880A1 (en) 2018-12-05
JP6866379B2 (ja) 2021-04-28
US10888543B2 (en) 2021-01-12
EP3407880B1 (en) 2022-08-17
JP2019502716A (ja) 2019-01-31
JP7153950B2 (ja) 2022-10-17
US11839600B2 (en) 2023-12-12
EP4104831A1 (en) 2022-12-21
US20240066003A1 (en) 2024-02-29
JP2022173373A (ja) 2022-11-18
US20190022052A1 (en) 2019-01-24
US11446275B2 (en) 2022-09-20
JP2021063136A (ja) 2021-04-22
US20220387373A1 (en) 2022-12-08
US10507196B2 (en) 2019-12-17
CA3012199A1 (en) 2017-08-03
US20210228532A1 (en) 2021-07-29
WO2017132127A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
US11839600B2 (en) Neurodevelopmental disorder therapy
US20210205262A1 (en) Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders
US11642326B2 (en) Prevention or remediation composition for dementia or depression
Ogata¹ et al. Selective serotonin reuptake inhibitors
ES2773834T3 (es) Métodos y composiciones para tratar la depresión usando ciclobenzaprina
JP2019059776A (ja) 不安障害患者の治療のためのナルメフェン
McDOUGLE et al. Risperidone in adults with autism or pervasive developmental disorder
JP2014508717A (ja) むちゃ食いまたは強迫性摂食を減少させるための方法
Pometlová et al. Cross-fostering effect on postnatal development of rat pups exposed to methamphetamine during gestation and preweaning periods
CN118871105A (zh) 鼻内奥氮平调配物及其使用方法
CN102099033B (zh) 用于治疗纤维肌痛症的药物组合物
HK40083948A (en) A2-73 for treating angelman syndrome, williams syndrome smith-magenis syndrome and multiple sclerosis
HK40000642B (en) Treatment of rett syndrome with the compound a2-73
HK40000642A (en) Treatment of rett syndrome with the compound a2-73
US20190151294A1 (en) Treatment of alcoholism and depression and/or dysphoric mood using ibudilast
Slezak et al. Further delineation between typical and atypical dopamine uptake inhibitors: effects on food-maintained behavior and food consumption
HK1155659B (en) Pharmaceutical composition for treatment of fibromyalgia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220119

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250117

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250117

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260116

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260116